Heide L. Ford

Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer

This study identifies Eya3 in macrophages as a checkpoint for anti-tumor immunity in TNBC, showing that its depletion or inhibition enhances immune responses and reduces tumor growth.

eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small molecules

The paper identifies eIF3d and eIF3e as mediators of hypoxia-induced translational control and shows that small molecules can inhibit this process.

Cryo-EM structures reveal the PP2A-B55α and Eya3 interaction that can be disrupted by a peptide inhibitor

The paper determines cryo-EM structures of PP2A-B55 and Eya3 interaction, showing how a peptide inhibitor disrupts this interaction and affects Myc stability in TNBC.

An EYA3/NF-κB/CCL2 signaling axis suppresses cytotoxic NK cells in the pre-metastatic niche to promote triple negative breast cancer metastasis

Potent synthetic lethality between PLK1 and EYA-family inhibitors in tumours of the central and peripheral nervous system

This study shows that combining EYA and PLK1 inhibitors is effective in treating neurological cancers by inducing cell death and targeting cancer stem cells.